Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycobacterium Vaccae (Mica) in Latent Tuberculosis Infection
NCT05680415Phase 4Active, not recruiting
- Sponsor
- Zhifei Biological
- Start
- Apr 2023
- Primary completion
- Sep 2026
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycobacterium vaccae in Tuberculosis (TB) (2 arms), sponsored by Zhifei Biological. Primary endpoint: Confirmed and Clinically Diagnosed Cases of Tuberculosis at 2 years. Started Apr 2023; status: active, not recruiting.
02
Drugs
mycobacterium vaccae
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05680415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05680415.